- Home
- RGNX vs MDXG Comparison
RGNX vs MDXG Comparison
Compare RGNX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGNX | MDXG |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.6M | 530.2M |
| IPO Year | 2015 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RGNX | MDXG |
|---|---|---|
| Price | $8.04 | $3.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $28.75 | $9.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | $10,393,000.00 | ★ $418,630,000.00 |
| Revenue This Year | $51.21 | N/A |
| Revenue Next Year | $19.08 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.48 | 19.99 |
| 52 Week Low | $5.46 | $3.03 |
| 52 Week High | $16.19 | $7.99 |
Technical Indicators
Market Signals| Indicator | RGNX | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 50.71 |
| Support Level | $5.67 | $3.47 |
| Resistance Level | $9.88 | $3.84 |
| Average True Range (ATR) | 0.57 | 0.13 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 67.37 | 47.50 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.